NCT00230529View on ClinicalTrials.gov

A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

Not specified

Study Completion Date

January 31, 2003

Conditions
Psoriasis
Interventions
DRUG

infliximab

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY

NCT00230529 - A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis | Biotech Hunter | Biotech Hunter